Expert Opinion on Emerging Drugs

Papers
(The TQCC of Expert Opinion on Emerging Drugs is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder66
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder22
Expert opinion on emerging drugs for lung chronic graft-versus-host disease20
Emerging drugs for the treatment of hepatocellular carcinoma19
Emerging drugs for hemophilia A: insights into phase II and III clinical trials17
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials14
Emerging drugs for the treatment of major depressive disorder13
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials13
Emerging therapeutics in Huntington’s disease12
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials12
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria11
Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients11
Emerging drugs for the treatment of alopecia areata10
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results10
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?10
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials9
Emerging drugs for the treatment of myasthenia gravis9
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?8
A review of phase II and III drugs for the treatment and management of endometriosis8
Recent advances in immune-based approaches for the treatment of esophagogastric cancer7
FcRn inhibitors in the context of myasthenia gravis7
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer’s disease?7
Mitapivat: a step forward across different hemolytic diseases7
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion6
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder6
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma6
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis5
Emerging drugs for the treatment of inflammatory bowel disease5
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?5
Emerging drugs for the treatment of postsurgical pain5
Letter to the editor: ‘Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa’5
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials5
Current and emerging drug treatment strategies to tackle sickle cell anemia5
Emerging drugs in the treatment of chronic cough5
An update on emerging drugs for the treatment of hypercholesterolemia5
0.18897914886475